Login to Your Account



Janssen Adcom Documents Look Promising for Gilead

By Mari Serebrov
Washington Editor

Wednesday, October 23, 2013
No big worries appear to be on the agenda for Thursday’s advisory committee meeting on Janssen Pharmaceuticals Inc.’s simeprevir, which is seeking a limited hepatitis C virus (HCV) label.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription